Overview

A concise scientific overview of deep and sustained treatment response in moderate‑to‑severe atopic dermatitis, highlighting the clinical impact of IL‑13 and IL‑4/13 pathway inhibition.

This Class for

Physician
Resident / Fellow

What I will learn?

Define deep and sustained response in moderate‑to‑severe atopic dermatitis.
Highlight the role of IL‑13 and IL‑4/13 pathways in disease control.
Understand the clinical rationale for targeting IL‑13 and IL‑4/13 in AD management.

Disclaimer

This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
(This information/content is intended to Health Care Providers only)

For adverse events and safety reporting: email: [email protected]

24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1

For Lilly product information: email: [email protected]

For further information, please contact:

Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: [email protected]
Please go to PDF Material for prescribing information.

PP-LK-SA-0195